Group items tagged Germany - health information

Novartis launches Lucentis PFS in Germany - 1 views

drugdelivery.pharmaceutical-business-review.com/...-pfs-in-germany-210314-4201632

health foods

shared by Alex Parker on 24 Mar 14 - No Cached

Alex Parker on 24 Mar 14

PBR Staff Writer Published 21 March 2014 Novartis has launched the Lucentis (ranibizumab) pre-filled syringe (PFS) in Germany and plans to introduce the product in other markets throughout 2014. In October 2013, the company has received approval from the European authorities for Lucentis PFS, which is a new way of administering Lucentis that is specifically designed for intraocular injection to enhance patient safety and convenience for the treating clinician.

<div class="cArrow"> </div><div class="cContentInner">PBR Staff Writer Published 21 March 2014 Novartis has launched the Lucentis (ranibizumab) pre-filled syringe (PFS) in Germany and plans to introduce the product in other markets throughout 2014. In October 2013, the company has received approval from the European authorities for Lucentis PFS, which is a new way of administering Lucentis that is specifically designed for intraocular injection to enhance patient safety and convenience for the treating clinician.</div>

...

Cancel

Live Workshop on Minimally Invasive Cardiac Surgery | Dr Gokhale CT Associates - 0 views

www.drgokhale.com/news-and-events.php

minimally invasive cardiac surgery in hyderabad best surgeon

shared by Dr AGK Gokhale on 18 Feb 15 - No Cached

Dr AGK Gokhale on 18 Feb 15

This is 3rd live workshop on minimal access cardiac surgery by this group. International faculty includes Dr Hendrik Treede from Germany and Prof Jayshankar Raman from Chicago.

<div class="cArrow"> </div><div class="cContentInner">This is 3rd live workshop on minimal access cardiac surgery by this group. International faculty includes Dr Hendrik Treede from Germany and Prof Jayshankar Raman from Chicago. </div>

...

Cancel

VB Curemart - The Role of Healthcare Facilitators in Medical Tourism - 0 views

Best_Hospitals_in_India best_treatment_in_India healthcare_facilities surgeries_in_India

shared by vbcuremart on 14 May 19 - No Cached

vbcuremart on 14 May 19

Medical tourism is growing by leaps and bounds as people realize the benefits of cost saving and the excellent treatment they receive in countries other than their own. People from the CIS, for instance, had to look to European countries like Germany, France, and the UK for treatment and in all these countries the treatment is expensive not to speak of stay and travel. Asian countries like India, Thailand and Sri Lanka are proving to be the better alternatives. The deterrent is how to find the best facility at the best cost and proceed. This is where a healthcare facilitator steps in and takes care of everything much to the relief of the patient and his family. The vital bridge Healthcare facilitators act as the vital bridge between the patient and the treatment facility that matches their needs. If you are in the US, UK, Australia, the CIS countries or in any African country and wish to find the best facility in India, for instance, the facilitator is the one to get in touch with. They maintain a database of hospitals and surgeons across the country, know their specialization and how much treatment can cost. Healthcare facilitators put you in touch with a medical institution that will give the best in terms of quality of treatment and cost. They do this by first going through your medical records and getting their panel of medical experts to match the ailment with a hospital. Patients get the benefit of expertise and save time and a great deal of money in the process. Patients receive invaluable assistance in: * Travel to the hospital * Scheduling appointments * Recommendations so that they receive personalized care * Supervision by the facilitator's own doctor to ensure that everything is being done right and, if not, patients may be switched to another hospital * Assistance with documentation and paperwork * Assistance with the procurement of medications * Negotiating the best rate with a discount for stay and treatment * Assistance to fam

<div class="cArrow"> </div><div class="cContentInner">Medical tourism is growing by leaps and bounds as people realize the benefits of cost saving and the excellent treatment they receive in countries other than their own. People from the CIS, for instance, had to look to European countries like Germany, France, and the UK for treatment and in all these countries the treatment is expensive not to speak of stay and travel. Asian countries like India, Thailand and Sri Lanka are proving to be the better alternatives. The deterrent is how to find the best facility at the best cost and proceed. This is where a healthcare facilitator steps in and takes care of everything much to the relief of the patient and his family. The vital bridge Healthcare facilitators act as the vital bridge between the patient and the treatment facility that matches their needs. If you are in the US, UK, Australia, the CIS countries or in any African country and wish to find the best facility in India, for instance, the facilitator is the one to get in touch with. They maintain a database of hospitals and surgeons across the country, know their specialization and how much treatment can cost. Healthcare facilitators put you in touch with a medical institution that will give the best in terms of quality of treatment and cost. They do this by first going through your medical records and getting their panel of medical experts to match the ailment with a hospital. Patients get the benefit of expertise and save time and a great deal of money in the process. Patients receive invaluable assistance in: * Travel to the hospital * Scheduling appointments * Recommendations so that they receive personalized care * Supervision by the facilitator's own doctor to ensure that everything is being done right and, if not, patients may be switched to another hospital * Assistance with documentation and paperwork * Assistance with the procurement of medications * Negotiating the best rate with a discount for stay and treatment * Assistance to fam</div>

...

Cancel

The Role of Healthcare Facilitators in Medical Tourism - 0 views

www.vbcuremart.com/choosingaMedicalValue

best_treatment_in_India Best_Hospitals_in_India surgeries in India

shared by vbcuremart on 09 May 19 - No Cached

vbcuremart on 09 May 19

Medical tourism is growing by leaps and bounds as people realize the benefits of cost saving and excellent treatment they receive in countries other than their own. People from the CIS, for instance, had to look to European countries like Germany, France and the UK for treatment and in all these countries the treatment is expensive not to speak of stay and travel. Asian countries like India, Thailand and Sri Lanka are proving to be the better alternatives. The deterrent is how to find the best facility at the best cost and proceed. This is where a healthcare facilitator steps in and takes care of everything much to the relief of the patient and his family. The vital bridge Healthcare facilitators act as the vital bridge between the patient and the treatment facility that matches their needs. If you are in the US, UK, Australia, the CIS countries or in any African country and wish to find the best facility in India, for instance, the facilitator is the one to get in touch with. They maintain database of hospitals and surgeons across the country, know their specialization and how much treatment can cost. Healthcare facilitators put you in touch with a medical institution that will give the best in terms of quality of treatment and cost. They do this by first going through your medical records and getting their panel of medical experts to match the ailment with a hospital. Patients get the benefit of expertise and save time and a great deal of money in the process. Patients receive invaluable assistance in: * Travel to the hospital * Scheduling appointments * Recommendations so that they receive personalized care * Supervision by the facilitator's own doctor to ensure that everything is being done right and, if not, patients may be switched to another hospital * Assistance with documentation and paper work * Assistance with procurement of medications * Negotiating the best rate with discount for stay and treatment * Assistance to family members

<div class="cArrow"> </div><div class="cContentInner">Medical tourism is growing by leaps and bounds as people realize the benefits of cost saving and excellent treatment they receive in countries other than their own. People from the CIS, for instance, had to look to European countries like Germany, France and the UK for treatment and in all these countries the treatment is expensive not to speak of stay and travel. Asian countries like India, Thailand and Sri Lanka are proving to be the better alternatives. The deterrent is how to find the best facility at the best cost and proceed. This is where a healthcare facilitator steps in and takes care of everything much to the relief of the patient and his family. The vital bridge Healthcare facilitators act as the vital bridge between the patient and the treatment facility that matches their needs. If you are in the US, UK, Australia, the CIS countries or in any African country and wish to find the best facility in India, for instance, the facilitator is the one to get in touch with. They maintain database of hospitals and surgeons across the country, know their specialization and how much treatment can cost. Healthcare facilitators put you in touch with a medical institution that will give the best in terms of quality of treatment and cost. They do this by first going through your medical records and getting their panel of medical experts to match the ailment with a hospital. Patients get the benefit of expertise and save time and a great deal of money in the process. Patients receive invaluable assistance in: * Travel to the hospital * Scheduling appointments * Recommendations so that they receive personalized care * Supervision by the facilitator's own doctor to ensure that everything is being done right and, if not, patients may be switched to another hospital * Assistance with documentation and paper work * Assistance with procurement of medications * Negotiating the best rate with discount for stay and treatment * Assistance to family members </div>

...

Cancel

New discovery facilitates blood test for mortality risk in elderly - 1 views

www.medicaldevice-network.com/...mortality-risk-test-elderly

#Blood_Test #New_Discovery_Facilities #Mortality_Risk #Researchers #Max_Planck_Institute #Blood_Biomarkers

shared by jacob logan on 23 Aug 19 - No Cached

jacob logan on 23 Aug 19

Researchers from the Max Planck Institute for Biology of Ageing in Germany and the Leiden University Medical Center (LUMC) in the Netherlands have discovered new blood biomarkers that could indicate a mortality risk in elderly people.

<div class="cArrow"> </div><div class="cContentInner"> Researchers from the Max Planck Institute for Biology of Ageing in Germany and the Leiden University Medical Center (LUMC) in the Netherlands have discovered new blood biomarkers that could indicate a mortality risk in elderly people.</div>

...

Cancel

Womb Cancer | Excess weight doubles risk : Researchers - 0 views

www.pharmacy.biz/rom-university-of-bristol-find

Obesity-and-endometrial-cancer pharmacy-business womb-cancer health-and-pharma-news Chances-of-endometrial-cancer obesity-and-womb-cancer Endometrial-cancer

shared by pharmacybiz on 20 Apr 22 - No Cached

pharmacybiz on 20 Apr 22

New research shows that lifelong excess weight almost doubles a woman's risk of developing womb cancer. The findings of the study were published in 'BMC Medicine'. The study from the University of Bristol is one of the first to find that for every fiver extra BMI units, a woman's risk of womb (endometrial) cancer is almost doubled (an increase of 88 per cent). This is higher than most previous studies have suggested and reflects lifelong weight status rather than a snapshot in time like most other studies. Five BMI units is the difference between the overweight category and the obese category, or of a 5'5 adult woman being two stones heavier. The international study looked at genetic samples from around 120,000 women from Australia, Belgium, Germany, Poland, Sweden, the UK, and the USA of which around 13,000 had womb cancer. This large statistical analysis is one of the first studies of its kind to look at the effect of lifelong greater BMI on womb cancer risk.

<div class="cArrow"> </div><div class="cContentInner">New research shows that lifelong excess weight almost doubles a woman's risk of developing womb cancer. The findings of the study were published in 'BMC Medicine'. The study from the University of Bristol is one of the first to find that for every fiver extra BMI units, a woman's risk of womb (endometrial) cancer is almost doubled (an increase of 88 per cent). This is higher than most previous studies have suggested and reflects lifelong weight status rather than a snapshot in time like most other studies. Five BMI units is the difference between the overweight category and the obese category, or of a 5'5 adult woman being two stones heavier. The international study looked at genetic samples from around 120,000 women from Australia, Belgium, Germany, Poland, Sweden, the UK, and the USA of which around 13,000 had womb cancer. This large statistical analysis is one of the first studies of its kind to look at the effect of lifelong greater BMI on womb cancer risk.</div>

...

Cancel

Nigel Stephenson :STADA appoints lead UK business - 0 views

www.pharmacy.biz/stephenson-to-lead-uk-business

nigel-stephenson-stada-appoints pharmacy-business pharmacy-news-uk stada-news community-pharmacy-news Independent-Community-Pharmacist Pharmacy-news-2023

shared by pharmacybiz on 10 Jul 23 - No Cached

pharmacybiz on 10 Jul 23

STADA has appointment Nigel Stephenson as General Manager UK with effect from 1 August 2023. Based in Huddersfield, UK, Stephenson will report directly to STADA's Head of Western Europe and Germany, Stephan Eder. He will take over from Rudolf Bär, who has successfully led the UK business for almost one year in addition to his responsibilities for STADA's Mid-Sized European Markets.| A dynamic and modern commercial leader with extensive experience in sales and marketing across Western, Central and Eastern Europe, and the UK in leading pharmaceutical, consumer healthcare and fast-moving consumer goods companies. He joins STADA from consumer healthcare leader Haleon, where he most recently served as General Manager Switzerland. "With his strong people and results orientation, along with deep purpose-driven engagement, Nigel will support our UK team in realizing its full potential through innovative and inclusive leadership," stated Eder.

<div class="cArrow"> </div><div class="cContentInner">STADA has appointment Nigel Stephenson as General Manager UK with effect from 1 August 2023. Based in Huddersfield, UK, Stephenson will report directly to STADA's Head of Western Europe and Germany, Stephan Eder. He will take over from Rudolf Bär, who has successfully led the UK business for almost one year in addition to his responsibilities for STADA's Mid-Sized European Markets.| A dynamic and modern commercial leader with extensive experience in sales and marketing across Western, Central and Eastern Europe, and the UK in leading pharmaceutical, consumer healthcare and fast-moving consumer goods companies. He joins STADA from consumer healthcare leader Haleon, where he most recently served as General Manager Switzerland. "With his strong people and results orientation, along with deep purpose-driven engagement, Nigel will support our UK team in realizing its full potential through innovative and inclusive leadership," stated Eder. </div>

...

Cancel

Thornton & Ross acquires Opticrom eye drops from Sanofi UK - 0 views

www.pharmacy.biz/icrom-eye-drops-from-sanofi-uk

thornton-&-ross-acquisition pharmacy-business thornton-&-ross-acquires-opticrom-eye-drops opticrom-eye-drops Sanofi-UK pharmacy-news-today Pharma-mergers-and-acquisitions-2023

shared by pharmacybiz on 17 Jul 23 - No Cached

pharmacybiz on 17 Jul 23

Thornton & Ross is all set to expand its consumer healthcare offering by acquiring the well-established Opticrom eye-drops brand from Sanofi in the UK. Opticrom forms part of a wider transaction between Thornton & Ross' parent group, STADA, and Sanofi for eight local consumer healthcare brands across several countries, including Belgium, Germany, Hungary, Spain and the UK. The transaction will be financed with a combination of cash on balance sheet and existing facilities, and is scheduled to close in the fourth quarter of 2023, subject to customary approvals of relevant regulatory authorities. Opticrom Allergy 10ml bottle and 20 single doses for itchy, watery, red and inflamed eyes can be found behind the pharmacy counter, while Opticrom Hayfever 10ml bottle is available to purchase via self-selection to soothe and relieve eye symptoms of hayfever. These non-prescription medicines contain 20 mg/1ml sodium cromoglicate (2.0% w/v) and offer relief within 2 minutes.

<div class="cArrow"> </div><div class="cContentInner">Thornton & Ross is all set to expand its consumer healthcare offering by acquiring the well-established Opticrom eye-drops brand from Sanofi in the UK. Opticrom forms part of a wider transaction between Thornton & Ross' parent group, STADA, and Sanofi for eight local consumer healthcare brands across several countries, including Belgium, Germany, Hungary, Spain and the UK. The transaction will be financed with a combination of cash on balance sheet and existing facilities, and is scheduled to close in the fourth quarter of 2023, subject to customary approvals of relevant regulatory authorities. Opticrom Allergy 10ml bottle and 20 single doses for itchy, watery, red and inflamed eyes can be found behind the pharmacy counter, while Opticrom Hayfever 10ml bottle is available to purchase via self-selection to soothe and relieve eye symptoms of hayfever. These non-prescription medicines contain 20 mg/1ml sodium cromoglicate (2.0% w/v) and offer relief within 2 minutes. </div>

...

Cancel

Pfizer, BioNTech countersue Moderna over vaccine patents - 0 views

www.pharmacy.biz/-over-covid-19-vaccine-patents

pfizer-vs-moderna pharmacy-business moderna-pfizer-vaccine-patent Lawsuit-against-Pfizer-COVID-vaccine Pfizer-vaccine-News lawsuit-against-pfizer

shared by pharmacybiz on 06 Dec 22 - No Cached

pharmacybiz on 06 Dec 22

Pfizer and its German partner, BioNTech, fired back at Moderna on Monday in a patent lawsuit over their rival Covid-19 vaccines, seeking dismissal of the lawsuit in Boston federal court and an order that Moderna's patents are invalid and not infringed. Moderna first sued Pfizer in August, accusing the company of violating its rights in three patents related to innovations that Cambridge, Massachusetts-based Moderna said it pioneered before the Covid-19 pandemic. Moderna has also filed a related lawsuit against Pfizer and BioNTech in Germany. All three companies are also embroiled in US patent disputes with other companies over the vaccines. A Pfizer spokesperson said the company and BioNTech are confident in their intellectual property and will "vigorously defend" against Moderna's claims. Moderna did not immediately respond to a request for comment on the Monday filing.

<div class="cArrow"> </div><div class="cContentInner">Pfizer and its German partner, BioNTech, fired back at Moderna on Monday in a patent lawsuit over their rival Covid-19 vaccines, seeking dismissal of the lawsuit in Boston federal court and an order that Moderna's patents are invalid and not infringed. Moderna first sued Pfizer in August, accusing the company of violating its rights in three patents related to innovations that Cambridge, Massachusetts-based Moderna said it pioneered before the Covid-19 pandemic. Moderna has also filed a related lawsuit against Pfizer and BioNTech in Germany. All three companies are also embroiled in US patent disputes with other companies over the vaccines. A Pfizer spokesperson said the company and BioNTech are confident in their intellectual property and will "vigorously defend" against Moderna's claims. Moderna did not immediately respond to a request for comment on the Monday filing.</div>

...

Cancel

Perrigo restructures management level:Strengthen local brands - 0 views

www.pharmacy.biz/urther-strengthen-local-brands

perrigo-brands pharmacy-business Ronald-van-Workum perrigo-brands-uk perrigo-dach-cluster-uk latest-pharmacy-news-uk pharmacy-updates-uk Perrigo-products-List

shared by pharmacybiz on 03 Feb 23 - No Cached

pharmacybiz on 03 Feb 23

Perrigo, one of the world's largest providers of self-care products has appointed Ronald van Workum as Sales Director Germany, Customer Strategy & Implementation DACH Cluster. van Workum will continue to drive the successful integration of HRA Pharma into the Perrigo network, with a focus on well-known brands such as Abtei, Compeed and Granu Fink. He most recently held the position of Head of Key Account Management for Perrigo in Europe, based in the Netherlands. Prior to joining Perrigo he worked for Procter & Gamble in several countries, including Singapore, and in various functions, including: Market Strategy Planning Manager for the Gillette brand; and in Europe as multifunctional Team Leader Emerging Channels. The company also announced Tobias Geiger has been promoted from his role as Finance Director of the Perrigo DACH Cluster, which he held since April 2020, to General Manager of the Perrigo DACH Cluster. During this time, he successfully supported the implementation and stabilisation of the DACH cluster. He also led several business optimisations with his teams, such as the implementation of SAP in Switzerland, process digitalisation and the creation of a DACH Finance Business Partner Model. Before joining Perrigo, Geiger worked for Sanofi for more than 10 years in various leadership positions in DACH and in Latin America.

<div class="cArrow"> </div><div class="cContentInner">Perrigo, one of the world's largest providers of self-care products has appointed Ronald van Workum as Sales Director Germany, Customer Strategy & Implementation DACH Cluster. van Workum will continue to drive the successful integration of HRA Pharma into the Perrigo network, with a focus on well-known brands such as Abtei, Compeed and Granu Fink. He most recently held the position of Head of Key Account Management for Perrigo in Europe, based in the Netherlands. Prior to joining Perrigo he worked for Procter & Gamble in several countries, including Singapore, and in various functions, including: Market Strategy Planning Manager for the Gillette brand; and in Europe as multifunctional Team Leader Emerging Channels. The company also announced Tobias Geiger has been promoted from his role as Finance Director of the Perrigo DACH Cluster, which he held since April 2020, to General Manager of the Perrigo DACH Cluster. During this time, he successfully supported the implementation and stabilisation of the DACH cluster. He also led several business optimisations with his teams, such as the implementation of SAP in Switzerland, process digitalisation and the creation of a DACH Finance Business Partner Model. Before joining Perrigo, Geiger worked for Sanofi for more than 10 years in various leadership positions in DACH and in Latin America.</div>

...

Cancel

Vani Manja:Boehringer Ingelheim Country MD - 0 views

www.pharmacy.biz/ector-and-head-of-human-pharma

Boehringer-ingelheim-uk pharmacy-business Boehringer-Ingelheim-UK-&-Ireland boehringer-ingelheim-md vani-manja-boehringer-ingelheim latest-pharmacy-news-uk

shared by pharmacybiz on 08 Feb 23 - No Cached

pharmacybiz on 08 Feb 23

Boehringer Ingelheim UK & Ireland has appointed Vani Manja as its new Country Managing Director and Head of Human Pharma. Manja has been associated with Boehringer Ingelheim for over 11 years, in successful leadership roles in Germany, the United States and most recently as General Manager, India. Her career started as a commissioned officer in the Indian Army Ordnance Corps which preceded leadership roles at Becton Dickinson and McKinsey. She brings extensive experience of strategy, marketing, sales, business development, people management, and cultural transformation and is passionate about tackling healthcare inequalities and advancing sustainable healthcare. Commenting on her new role, Manja said: "It is with great heart that I bring the spirit of conscious leadership to my new role. I look forward to being fully present and partnering with key stakeholders in the healthcare ecosystem in our collective quest to improve health for humans and animals in the UK and Ireland."

<div class="cArrow"> </div><div class="cContentInner">Boehringer Ingelheim UK & Ireland has appointed Vani Manja as its new Country Managing Director and Head of Human Pharma. Manja has been associated with Boehringer Ingelheim for over 11 years, in successful leadership roles in Germany, the United States and most recently as General Manager, India. Her career started as a commissioned officer in the Indian Army Ordnance Corps which preceded leadership roles at Becton Dickinson and McKinsey. She brings extensive experience of strategy, marketing, sales, business development, people management, and cultural transformation and is passionate about tackling healthcare inequalities and advancing sustainable healthcare. Commenting on her new role, Manja said: "It is with great heart that I bring the spirit of conscious leadership to my new role. I look forward to being fully present and partnering with key stakeholders in the healthcare ecosystem in our collective quest to improve health for humans and animals in the UK and Ireland."</div>

...

Cancel

MHRA Alert on Semaglutide Risks : Safeguard Your Health: - 0 views

www.pharmacy.biz/...uk-wholesalers-selling-ozempic

Dr-Alison-Cave MHRA-Chief-Safety-Officer Semaglutide Risk-of-Falsified-Medicines UK-Medicine-Safety MHRA-Safety-Concerns Buying-Semaglutide-Online Yellow-Card-Scheme

shared by pharmacybiz on 23 Oct 23 - No Cached

pharmacybiz on 23 Oct 23

The Medicines and Healthcare Products Regulatory Agency (MHRA) confirmed that Ozempic has been found at two UK wholesalers on 18 October. The pre-filled falsely labelled pens have been purchased from legitimate suppliers in Austria and Germany. However, there has been no evidence that fake Ozempic has been supplied to UK patients. Dr Alison Cave, MHRA Chief Safety Officer spoke about closely with regulatory partners to ensure patients' safety. He said: "Buying semaglutide from illegally trading online suppliers significantly increases the risk of getting a product either falsified or not licensed for use in the UK. "Products purchased in this way will not meet our strict quality and safety standards, and taking such medicines may put your health at risk," he added.

<div class="cArrow"> </div><div class="cContentInner">The Medicines and Healthcare Products Regulatory Agency (MHRA) confirmed that Ozempic has been found at two UK wholesalers on 18 October. The pre-filled falsely labelled pens have been purchased from legitimate suppliers in Austria and Germany. However, there has been no evidence that fake Ozempic has been supplied to UK patients. Dr Alison Cave, MHRA Chief Safety Officer spoke about closely with regulatory partners to ensure patients' safety. He said: "Buying semaglutide from illegally trading online suppliers significantly increases the risk of getting a product either falsified or not licensed for use in the UK. "Products purchased in this way will not meet our strict quality and safety standards, and taking such medicines may put your health at risk," he added.</div>

...

Cancel

Hypertension And Diabetes Are Linked :Scientists - 0 views

www.pharmacy.biz/s-for-new-treatment-strategies

latest-blood-pressure-news pharmacy-business Blood-pressure-breakthrough-2021 Research-on-high-blood-pressure Latest-research-on-high-blood-pressure hypertension-and-diabetes-treatment

shared by pharmacybiz on 02 Feb 22 - No Cached

pharmacybiz on 02 Feb 22

One of the long-standing medical mysteries is the diagnosis of diabetes in majority of patients suffering from high blood pressure. The reason for this had been unknown. But now, an international team of universities have made a breakthrough. The research, published online in 'Circulation Research', involved contributions from collaborating scientists in Brazil, Germany, Lithuania, and Serbia, as well as the UK and New Zealand. The important new discovery has shown that a small protein cell glucagon-like peptide-1 (GLP-1) couples the body's control of blood sugar and blood pressure. Professor Julian Paton, a senior author, and director of Manaaki Manawa, The Centre for Heart Research at the University of Auckland, said: "We've known for a long time that hypertension and diabetes are inextricably linked and have finally discovered the reason, which will now inform new treatment strategies." GLP-1 is released from the wall of the gut after eating and acts to stimulate insulin from the pancreas to control blood sugar levels. This was known but what has now been unearthed is that GLP-1 also stimulates a small sensory organ called the carotid body located in the neck.

<div class="cArrow"> </div><div class="cContentInner">One of the long-standing medical mysteries is the diagnosis of diabetes in majority of patients suffering from high blood pressure. The reason for this had been unknown. But now, an international team of universities have made a breakthrough. The research, published online in 'Circulation Research', involved contributions from collaborating scientists in Brazil, Germany, Lithuania, and Serbia, as well as the UK and New Zealand. The important new discovery has shown that a small protein cell glucagon-like peptide-1 (GLP-1) couples the body's control of blood sugar and blood pressure. Professor Julian Paton, a senior author, and director of Manaaki Manawa, The Centre for Heart Research at the University of Auckland, said: "We've known for a long time that hypertension and diabetes are inextricably linked and have finally discovered the reason, which will now inform new treatment strategies." GLP-1 is released from the wall of the gut after eating and acts to stimulate insulin from the pancreas to control blood sugar levels. This was known but what has now been unearthed is that GLP-1 also stimulates a small sensory organ called the carotid body located in the neck.</div>

...

Cancel

AstraZeneca:Drug combo helps late-stage ovarian cancer trial - 0 views

www.pharmacy.biz/ate-stage-ovarian-cancer-trial

AstraZeneca-cancer-drug-combo pharmacy-business astrazeneca-news astrazeneca-cancer-drugs astrazeneca-ovarian-cancer-drug lynparza-ovarian-cancer astrazeneca-uk

shared by pharmacybiz on 06 Apr 23 - No Cached

pharmacybiz on 06 Apr 23

AstraZeneca on Wednesday (April 5) said a combination of its cancer drugs Imfinzi and Lynparza met the main goal in a late-stage trial in patients with advanced ovarian cancer. The drugmaker said treatment with a combination of those drugs, along with chemotherapy and bevacizumab - the existing standard of care - improved progression-free survival in newly diagnosed patients with advanced ovarian cancer without certain mutations. Lynparza is jointly developed with U.S.-based Merck & Co as a treatment for breast cancer in early stage with certain mutations. Imfinzi alone, along with chemotherapy and bevacizumab, did not reach statistical significance in its interim analysis, the drugmaker added. Philipp Harter, director, Department of Gynaecology and Gynaecologic Oncology, Evangelische Kliniken Essen-Mitte, Germany and principal investigator for the trial, said: "DUO-O showcases the power of academia and industry collaboration in advancing new treatment combinations for patients with ovarian cancer. I'm grateful for the academic cooperative study groups and patients around the world that made this trial possible and look forward to sharing the results with the clinical community." Susan Galbraith, executive vice president, Oncology R&D, AstraZeneca, said: "While there has been significant progress for patients with advanced ovarian cancer, an unmet need still remains. These data from the DUO-O trial provide encouraging evidence for this this Lynparza and Imfinzi combination in patients without tumour BRCA mutations and reinforce our continued commitment to finding new treatment approaches for these patients. It will be important to understand the key secondary endpoints as well as data for relevant subgroups."

<div class="cArrow"> </div><div class="cContentInner">AstraZeneca on Wednesday (April 5) said a combination of its cancer drugs Imfinzi and Lynparza met the main goal in a late-stage trial in patients with advanced ovarian cancer. The drugmaker said treatment with a combination of those drugs, along with chemotherapy and bevacizumab - the existing standard of care - improved progression-free survival in newly diagnosed patients with advanced ovarian cancer without certain mutations. Lynparza is jointly developed with U.S.-based Merck & Co as a treatment for breast cancer in early stage with certain mutations. Imfinzi alone, along with chemotherapy and bevacizumab, did not reach statistical significance in its interim analysis, the drugmaker added. Philipp Harter, director, Department of Gynaecology and Gynaecologic Oncology, Evangelische Kliniken Essen-Mitte, Germany and principal investigator for the trial, said: "DUO-O showcases the power of academia and industry collaboration in advancing new treatment combinations for patients with ovarian cancer. I'm grateful for the academic cooperative study groups and patients around the world that made this trial possible and look forward to sharing the results with the clinical community." Susan Galbraith, executive vice president, Oncology R&D, AstraZeneca, said: "While there has been significant progress for patients with advanced ovarian cancer, an unmet need still remains. These data from the DUO-O trial provide encouraging evidence for this this Lynparza and Imfinzi combination in patients without tumour BRCA mutations and reinforce our continued commitment to finding new treatment approaches for these patients. It will be important to understand the key secondary endpoints as well as data for relevant subgroups."</div>

...

Cancel

OctreoPharm's OPS202 gets EMA orphan drug designation for management of GEP-NETs - 0 views

regulatoryaffairs.pharmaceutical-business-review.com/...manage-gep-nets-300114-4168590

health Treatment generic

shared by Alex Parker on 31 Jan 14 - No Cached

Alex Parker on 31 Jan 14

Germany-based OctreoPharm Sciences has received Orphan Drug Designation from the European Medicines Agency (EMA) for OPS202 as a diagnostic agent for the management of patients with gastro-entero-pancreatic-neuroendocrine tumors

<div class="cArrow"> </div><div class="cContentInner">Germany-based OctreoPharm Sciences has received Orphan Drug Designation from the European Medicines Agency (EMA) for OPS202 as a diagnostic agent for the management of patients with gastro-entero-pancreatic-neuroendocrine tumors</div>

...

Cancel

Boehringer's Pradaxa gets FDA approval for DVT, PE treatment - 1 views

regulatoryaffairs.pharmaceutical-business-review.com/...vt-pe-treatment-090414-4211375

Health treatment

shared by Alex Parker on 09 Apr 14 - No Cached

Alex Parker on 09 Apr 14

Germany-based pharmaceutical firm Boehringer Ingelheim has received approval from the US Food and Drug Administration (FDA) for Pradaxa (dabigatran etexilate) to treat venous thromboembolism (VTE), which includes both deep venous thrombosis (DVT) and pulmonary embolism (PE).

<div class="cArrow"> </div><div class="cContentInner">Germany-based pharmaceutical firm Boehringer Ingelheim has received approval from the US Food and Drug Administration (FDA) for Pradaxa (dabigatran etexilate) to treat venous thromboembolism (VTE), which includes both deep venous thrombosis (DVT) and pulmonary embolism (PE).</div>

...

Cancel

Evotec, Debiopharm to research and develop new cancer treatments - 1 views

contractresearch.pharmaceutical-business-review.com/...ncer-treatments-030414-4208083

health treatment

shared by Alex Parker on 04 Apr 14 - No Cached

Alex Parker on 04 Apr 14

Germany based drug discovery firm Evotec has entered into a research collaboration and licensing deal with Swiss biopharmaceutical firm Debiopharm Group to research and develop new cancer treatments

<div class="cArrow"> </div><div class="cContentInner">Germany based drug discovery firm Evotec has entered into a research collaboration and licensing deal with Swiss biopharmaceutical firm Debiopharm Group to research and develop new cancer treatments</div>

...

Cancel

Liquid Cod Liver Oil - 2 views

fishyoil.com/...liquid-cod-liver-oil

Pure Liquid Cod Liver Oil China Germany

shared by Fishy Oil on 03 Dec 15 - No Cached

Fishy Oil on 03 Dec 15

Are you also amongst the ones suffering from asthma, psychiatrist disorder, arthritis or heart diseases? No need to worry at all! Order liquid cod liver oil from Fishy Oil and get rid of all these.

<div class="cArrow"> </div><div class="cContentInner">Are you also amongst the ones suffering from asthma, psychiatrist disorder, arthritis or heart diseases? No need to worry at all! Order liquid cod liver oil from Fishy Oil and get rid of all these.</div>

...

Cancel
Fishy Oil on 04 Feb 16

Do you have heart disease, asthma, psoriasis, arthritis, or a psychiatric disorder? Evidence gathered by selective research facilities has theorized that cod liver oil has effective defensive properties to reduce the occurrence of these diseases. The defensive properties include Vitamin D, A, E, and loads of Omega-3 fatty acids.

<div class="cArrow"> </div><div class="cContentInner">Do you have heart disease, asthma, psoriasis, arthritis, or a psychiatric disorder? Evidence gathered by selective research facilities has theorized that cod liver oil has effective defensive properties to reduce the occurrence of these diseases. The defensive properties include Vitamin D, A, E, and loads of Omega-3 fatty acids.</div>

...

Cancel

Omega-3 Calcium + D Vitamin - 1 views

fishyoil.com/...omega-3-calcium-d-vitamin

Children's cod liver oil Health benefits of Fish supplement Germany

shared by Fishy Oil on 09 Feb 16 - No Cached

Fishy Oil on 09 Feb 16

Omega-3 calcium + D vitamin is one of the best things you can opt for in order to prevent becoming ill with osteoporosis. It lets your body to utilize the maximum level of calcium and reduces the risk of osteoporosis efficiently.

<div class="cArrow"> </div><div class="cContentInner">Omega-3 calcium + D vitamin is one of the best things you can opt for in order to prevent becoming ill with osteoporosis. It lets your body to utilize the maximum level of calcium and reduces the risk of osteoporosis efficiently.</div>

...

Cancel

Children's Cod Liver Oil - 2 views

fishyoil.com/...childrens-cod-liver-oil

Children's Cod Liver Oil Liquid Germany Children´s Omega-3 Chewable

shared by Fishy Oil on 05 Feb 16 - No Cached

Fishy Oil on 05 Feb 16

As a parent, you want your kids to grow up to be healthy adults. You can start now by providing your little ones with Children's Cod Liver Oil. The medicine contains omega-3 fatty acids, vitamin A, E, D, and DHA.

<div class="cArrow"> </div><div class="cContentInner">As a parent, you want your kids to grow up to be healthy adults. You can start now by providing your little ones with Children's Cod Liver Oil. The medicine contains omega-3 fatty acids, vitamin A, E, D, and DHA.</div>

...

Cancel

Group items tagged